Results of Expert Council meeting on modern principles of treatment optimization in patients with relapsing-remitting multiple sclerosis using anti-CD20 monoclonal antibody

The article presents the results of the discussion of the use of anti-B-cell therapy in multiple sclerosis (MS). These cells play a significant role in immunoregulation in MS, not only by producing antibodies to myelin antigens after transformation into plasma cells, but also by presenting the antigen to T cells, producing activation cytokines, and forming laminar follicles. The article provides an expert consensus statement on different drugs of this class in the MS treatment. In addition, the possibilities of determining the disease prognosis for the initially correct treatment choice are highlighted. Undoubtedly, there is a need for confirmation of the MS diagnosis, possible stratification of patients into different risk groups, and evaluation of the response to therapy. Potential additional research methods included evoked potentials and optical coherence tomography, baseline vitamin D3 level as a prognostic marker of the disease course, neurofilament levels in serum and cerebrospinal fluid to confirm neuron damage. However, it takes much time to study, determine the methodology, reference values, and develop a single standard approach to identify and implement a biomarker, which should then be implemented in routine clinical practice.

1. Milo R. Ofatumumab – A Potential Subcutaneous B-cell Therapy for Relapsing Multiple Sclerosis. Eur Neuro Rev. 2020;15(1):1-7. doi: 10.17925/ENR.2020.15.1.27

2. Wang K, Song F, Fernandez-Escobar A, et al. The Properties of Cytokines in Multiple Sclerosis: Pros and Cons. Am J Med Sci. 2018;356(6):552- 60. doi: 10.1016/j.amjms.2018.08.018. Epub 2018 Sep 5.

3. Imitola J, Chitnis T, Khoury SJP. Cytokines in multiple sclerosis: from bench to bedside. Phharmacol Ther. 2005;106(2):163-77. doi: 10.1016/j.pharmthera.2004.11.007

4. Li R, Patterson KR, Bar-Or A. Reassessing B cell contributions in multiple sclerosis. Nat Immunol. 2018 Jul;19(7):696-707. doi: 10.1038/s41590-018-0135-x. Epub 2018 Jun 20.

5. Gusev EI, Boyko AN, Stolyarov ID. Rasseyannyy skleroz [Multiple sclerosis]. Moscow: Real Taym; 2015 (In Russ.).

6. Haider L, Zrzavy T, Hametner S, et al. The topograpy of demyelination and neurodegeneration in the multiple sclerosis brain. Brain. 2016 Mar;139(Pt 3):807-15. doi: 10.1093/brain/awv398. Epub 2016 Feb 8.

7. Michel L, Touil H, Pikor N, et al. B Cells in the multiple sclerosis central nervous system: trafficking and contribution to CNS-compartmentalized inflammation. Front Immunol. 2015 Dec 24;6:636. doi: 10.3389/fimmu.2015.00636. eCollection 2015.

8. Milo R. Therapeutic strategies targeting Bcells in multiple sclerosis. Autoimmun Rev. 2016 Jul;15(7):714-8. doi: 10.1016/j.autrev.2016.03.006. Epub 2016 Mar 9.

9. Wekerle H. B cells in multiple sclerosis. Autoimmunity. 2017 Feb;50(1):57-60. doi: 10.1080/08916934.2017.1281914

10. Boyko AN, Lashch NYu, Guseva ME. New drugs for anti-B-cell therapy of multiple sclerosis. Nevrologiya, neiropsikhiatriya, psikhosomatika = Neurology, Neuropsychiatry, Psychosomatics. 2018;10(1):70-3. doi: 10.14412/2074-2711-2018-1-70-73 (In Russ.).

11. Ryabov SA, Boyko AN. Rehabilitation of patients with multiple sclerosis in terms of evidence-based medicine: techniques for digitizing the results. Nevrologiya, neiropsikhiatriya, psikhosomatika = Neurology, Neuropsychiatry, Psychosomatics. 2020;12(Suppl. 1):38-43. doi: 10.14412/2074-2711-2020-1S-38-43 (In Russ.).

12. Sivertseva SA, Belkin AA, Zotova AV, et al. The impact of rehabilitation on the mobility and quality of life of patients with multiple sclerosis. Zhurnal nevrologii i psikhiatrii im. S.S. Korsakova. 2020;120(7-2):154 (In Russ.).

13. Hauser SL, Bar-Or A, Cohen JA, et al; ASCLEPIOS I and ASCLEPIOS II Trial Groups. Ofatumumab versus Teriflunomide in Multiple Sclerosis. N Engl J Med. 2020 Aug 6;383(6):546-57. doi: 10.1056/NEJMoa1917246

14. Boyko OV, Khoroshilova II, Petrov SV, et al. Changes in the quality of life of patients with multiple sclerosis during treatment with ocrelizumab. Zhurnal nevrologii i psikhiatrii im. S.S. Korsakova. Spetsvypuski. 2019;119(10- 2):120-7. doi: 10.17116/jnevro201911910120 (In Russ.).

15. The IFNB Multiple Sclerosis Study Group, Interferon beta-1b Is Effective in RelapsingRemitting Multiple Sclerosis. I. Clinical Results of a Multicenter, Randomized, Double-Blind, Placebo-Controlled Trial. The IFNB Multiple Sclerosis Study Group. Neurology. 1993 Apr;43(4):655-61. doi: 10.1212/wnl.43.4.655

16. The IFNB Multiple Sclerosis Study Group, the University of British Columbia MS/MRI Analysis Group. Interferon beta-1b in the Treatment of Multiple Sclerosis: Final Outcome of the Randomized Controlled Trial. The IFNB Multiple Sclerosis Study Group and The University of British Columbia MS/MRI Analysis Group. Neurology. 1995 Jul;45(7):1277-85.

17. Ebers GC, Traboulsee A, Li D, et al; Investigators of the 16-year Long-Term FollowUp Study. Analysis of Clinical Outcomes According to Original Treatment Groups 16 Years After the Pivotal IFNB-1b Trial. J Neurol Neurosurg Psychiatry. 2010 Aug;81(8):907-12. doi: 10.1136/jnnp.2009.204123. Epub 2010 Jun 19.

18. Stankiewicz JM, Weiner HL. An argument for broad use of high efficacy treatments in early multiple sclerosis. Neurol Neuroim Neuroinflamm. 2019 Nov 22;7(1):e636. doi: 10.1212/NXI.0000000000000636. Print 2020 Jan.

19. Dubuisson N, Puentes F, Giovannoni G, Gnanapavan S. Science is 1% inspiration and 99% biomarkers. Mult Scler. 2017 Oct;23(11):1442-52. doi: 10.1177/1352458517709362. Epub 2017 May 24.